Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William H. Carson bought 3,200 shares of the company's stock in a transaction dated Monday, July 1st. The stock was bought at an average cost of $5.00 per share, with a total value of $16,000.00. Following the transaction, the director now directly owns 12,800 shares in the company, valued at approximately $64,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Annexon Stock Down 9.6 %
Annexon stock opened at $4.57 on Wednesday. The firm has a 50-day moving average price of $4.99 and a two-hundred day moving average price of $5.08. The firm has a market capitalization of $421.85 million, a price-to-earnings ratio of -3.11 and a beta of 1.29. Annexon, Inc. has a 52-week low of $1.57 and a 52-week high of $8.40.
Annexon (NASDAQ:ANNX - Get Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.11. Research analysts expect that Annexon, Inc. will post -0.98 earnings per share for the current year.
Institutional Inflows and Outflows
Biden to drop out; finish out his term?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
A number of hedge funds and other institutional investors have recently bought and sold shares of ANNX. BVF Inc. IL acquired a new position in Annexon during the 4th quarter valued at about $31,780,000. Bain Capital Life Sciences Investors LLC raised its position in shares of Annexon by 41.4% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company's stock worth $36,600,000 after buying an additional 2,359,793 shares in the last quarter. Bellevue Group AG bought a new stake in shares of Annexon during the 1st quarter worth about $15,647,000. Vanguard Group Inc. raised its position in shares of Annexon by 96.4% during the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company's stock worth $26,871,000 after buying an additional 1,839,329 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Annexon by 10,482.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,323,704 shares of the company's stock worth $9,492,000 after buying an additional 1,311,195 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Annexon from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, May 15th. JPMorgan Chase & Co. lifted their price target on shares of Annexon from $11.00 to $13.00 and gave the company an "overweight" rating in a report on Monday, April 1st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a report on Wednesday, June 5th. Bank of America lifted their price target on shares of Annexon from $7.00 to $10.00 and gave the company a "buy" rating in a report on Thursday, March 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, June 4th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $15.33.
Get Our Latest Research Report on Annexon
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
